Results 131 to 140 of about 352,696 (330)

Lung clearance index short-term variability in cystic fibrosis: a pre-post pulmonary exacerbation study

Italian Journal of Pediatrics
Background Multiple Breath washout (MBW) represents an important tool to detect early a possible pulmonary exacerbation especially in Cystic Fibrosis (CF) disease.
Matteo De Marchis, Enza Montemitro, Alessandra Boni, Alessandra Federici, Daniele Di Giovanni, Luca Cristiani, Renato Cutrera, Alessandro G. Fiocchi   +7 more
doaj   +1 more source

EFFECTS OF ACETYLCHOLINE ON THE INCORPORATION OF P32 INTO THE PHOSPHOLIPIDS IN SLICES OF SKIN FROM CHILDREN WITH AND WITHOUT CYSTIC FIBROSIS OF THE PANCREAS* [PDF]

, 1963
Lowell E. Hokin, Mabel R. Hokin, Charles C. Lobeck   +2 more
openalex   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source

Anesthetic Experience in Children with Cystic Fibrosis of the Pancreas [PDF]

, 1964
Ernest Salanitre, D. H. Klonymus, Herbert Rackow   +2 more
openalex   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Rapid method for the detection of cystic fibrosis of the pancreas in children. [PDF]

, 1967
B. A. Saggers, D. Lawson, J. Stern, A. C. Edgson   +3 more
openalex   +1 more source

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models

Clinical Pharmacology &Therapeutics, EarlyView.
The use of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety ...
Eunjin Hong, Mary F. Hebert, Emily Fay, Grant Turner, Patricia Eshaghian, Aaron Trimble, Peter S. Chung, Adupa P. Rao, Paul M. Beringer   +8 more
wiley   +1 more source

Screening for cystic fibrosis by measurement of unstimulated parotid saliva sodium levels. [PDF]

, 1967
D. Lawson, B. A. Saggers, M. John Chapman   +2 more
openalex   +1 more source

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Autosomal dominant polycystic kidney disease is the most prevalent inherited kidney disease and leads to bilateral kidney enlargement and progressive loss of renal function, often over decades. Comorbidities include hypertension, flank pain, and bacterial infections. The condition often necessitates prolonged multidrug therapy.
Annika C. Tillmann, Dorien J. M. Peters, Amin Rostami‐Hodjegan, Patricia Wilson, Jill Norman, Jill Barber, Zubida M. Al‐Majdoub   +6 more
wiley   +1 more source

Side-effects to antibiotics in cystic fibrosis. I: ocular changes in relation to antibiotic administration and to severity of pulmonary involvement. [PDF]

, 1966
C G Keith, Jordan D. Haller, William F. Young   +2 more
openalex   +1 more source